USFDA Reports Cipla's Recall of 400+ Cancer Drug Cartons in US

Entertainment National Sports Markets Business & Economy Lifestyle World Astrology & Religion Technology Education & Jobs Auto Politics Viral Opinions

Loading more articles...

Cipla USA Recalls Over 400 Cartons of Cancer Drug Nilotinib Due to Manufacturing Issue

Representational image (Image: News18)

N

News18•08-03-2026, 11:00

Cipla USA Recalls Over 400 Cartons of Cancer Drug Nilotinib Due to Manufacturing Issue

•Cipla USA, Inc, a US-based subsidiary of drugmaker Cipla, is recalling over 400 cartons of its generic anti-cancer medication in the US.
•The recalled drug is Nilotinib Capsules, available in 150 mg and 200 mg strengths.
•The recall, initiated on February 18, is due to "failed tablet/capsule specifications" related to a manufacturing issue.
•It is a Class III voluntary recall, meaning the product is not likely to cause adverse health consequences.
•Nilotinib works by blocking abnormal proteins to stop or slow the spread of cancer cells.

Read Full Article on News18 in English

✦

More like this

✦

More like this

Natco Pharma | Announces the launch of Pomalidomide Capsules in the US market used in the treatment of Adult patients with Multiple Myeloma. These capsules had estimated sales of $3.2 billion in the US for the 12 months that ended in September 2025.

Natco Pharma shares gain 3% on US launch of multiple myeloma drug

Representational image (Image: News18)

NATCO Pharma Launches Generic Blood Cancer Drug in US Market

Cipla | The company has entered into a 60:40 JV agreement with Kemwell Biopharma Pvt. Ltd. to incorporate a JV company in India. The JV will undertake the business of developing, applying for and obtaining licenses for manufacturing, commercializing, importing and exporting biologic products and licensing or outsourcing of any or all such activities. Kemwell offers end-to-end services for Global biopharma clients and has a unit in Bengaluru certified by the USFDA, which includes 5,000L bioreactor capacity, sterile fill–finish, and advanced development labs for protein therapeutics.

Cipla Recalls Key US Drug Lanreotide, Faces Temporary Shortage & Margin Cut

Glenmark Pharma Launches Key Injection in US, Eyes $50.7M Market Share

Glenmark Pharma Launches Key Injection in US, Eyes $50.7M Market Share

Tuesday, November 11, 2025 | Aavas Financiers, Atlanta Electricals, Atul Auto, Awfis Space Solutions, Bajaj Finserv, Balrampur Chini, Bharat Forge, Bikaji, Biocon, BLS International, Bosch, Borosil Renewables, Ciegall India, Cera Sanitaryware, CONCOR, Cosmo First, Dhampur Sugar, Ecos Mobility, Edelweiss, EID Parry, Emcure Pharma, EPL, ESAF SFB, Finolex Cables, Fortis Healthcare, GMR Power, Godrej Industries, Gokaldas Exports, GSFC, GSPL, Hindustan Copper, HT Media, Indo Count, IFCI, IOL Chemicals, JB Chemicals, Jupiter Wagons, Kolte Patil, Laxmi Dental, Manba Finance, MOIL, One Source, Orchid Pharma, Parag Milk, PC Jewellers, Rategain, RITES, RVNL, Subex, Surya Roshni, Suven Pharma, Tata Power, Texmaco Rail, Thermax, Torrent Power, TransRail Lighting, TVS Srichakra, Yatra Online, Zaggle,

Biocon gets USFDA nod for Liraglutide injection gSaxenda for weight management

Nifty Prediction For Monday, February 23.

Nifty Set for Gap-Up Opening After US Tariffs Cut to 15%